FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205253670> ?p ?o ?g. }

• W3205253670 endingPage "S85" @default.
• W3205253670 startingPage "S84" @default.
• W3205253670 abstract "BACKGROUNDAtherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality in Canada and worldwide. Laboratory tests, including troponin and low-density lipoprotein cholesterol (LDL-C), are important biomarkers of ASCVD risk. The objective of this study was to investigate patterns of testing for troponin and LDL-C test volumes among Alberta residents during the coronavirus disease 2019 (COVID-19) pandemic.METHODS AND RESULTSA repeated cross-sectional study design captured population-level laboratory test volumes between March 15, 2019 and December 14, 2020. Three-month cross-sections were derived to report laboratory test volumes by different COVID-19 restriction periods during 2020-2021 and using 2019-2020 as a preceding control period. Percent change for troponin and LDL-C test volumes were calculated for both control and COVID-19 periods among adult (≥18 years of age) Alberta residents, and stratified by age (18-49, 50-65, 66-79, and ≥80 years), sex, and geographic zones (urban, rural). This preliminary data is part of an ongoing study for which further troponin and LDL-C test volumes will be available up until March 14, 2021 (representing one year of data throughout the COVID-19 pandemic). Among the Alberta population, 292,836 troponin and 794,789 LDL-C tests were captured between March 15, 2020 and December 14, 2020 (Figure 1). Testing patterns during the COVID-19 restriction period showed marked reduction in test volumes from the previous year. The initial cross-section of the COVID-19 period (March-June 2020) was characterized by the largest overall reduction with troponin test volumes decreasing 18% and LDL-C test volumes decreasing 63%, compared to the year prior. As restrictions eased in the summer months of 2020, testing volumes rebounded to near pre-pandemic volumes for both tests. However, in the fall of 2020, troponin tests decreased again (-15%). Within these drops in utilization, slightly larger relative declines were observed for troponin test volumes in women (-20%) and patients ≥80 years-old (-25%) and for LDL-C test volumes among urban residents (-64%), women (-67%) and patients aged 18-49 (-66%) and 50-65 (-65%) years (Table 1).CONCLUSIONThis study describes declines in troponin and LDL-C test volumes in the initial and second COVID-19 lockdown periods. Women had overall smaller total troponin and LDL-C test volumes and larger relative declines during the pandemic compared to men. The decrease in these ASCVD-related laboratory test volumes during the pandemic may have been accompanied by other important changes in indicators of healthcare utilization and associated clinical outcomes. Ongoing analyses will further explore the impact of the pandemic. Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality in Canada and worldwide. Laboratory tests, including troponin and low-density lipoprotein cholesterol (LDL-C), are important biomarkers of ASCVD risk. The objective of this study was to investigate patterns of testing for troponin and LDL-C test volumes among Alberta residents during the coronavirus disease 2019 (COVID-19) pandemic. A repeated cross-sectional study design captured population-level laboratory test volumes between March 15, 2019 and December 14, 2020. Three-month cross-sections were derived to report laboratory test volumes by different COVID-19 restriction periods during 2020-2021 and using 2019-2020 as a preceding control period. Percent change for troponin and LDL-C test volumes were calculated for both control and COVID-19 periods among adult (≥18 years of age) Alberta residents, and stratified by age (18-49, 50-65, 66-79, and ≥80 years), sex, and geographic zones (urban, rural). This preliminary data is part of an ongoing study for which further troponin and LDL-C test volumes will be available up until March 14, 2021 (representing one year of data throughout the COVID-19 pandemic). Among the Alberta population, 292,836 troponin and 794,789 LDL-C tests were captured between March 15, 2020 and December 14, 2020 (Figure 1). Testing patterns during the COVID-19 restriction period showed marked reduction in test volumes from the previous year. The initial cross-section of the COVID-19 period (March-June 2020) was characterized by the largest overall reduction with troponin test volumes decreasing 18% and LDL-C test volumes decreasing 63%, compared to the year prior. As restrictions eased in the summer months of 2020, testing volumes rebounded to near pre-pandemic volumes for both tests. However, in the fall of 2020, troponin tests decreased again (-15%). Within these drops in utilization, slightly larger relative declines were observed for troponin test volumes in women (-20%) and patients ≥80 years-old (-25%) and for LDL-C test volumes among urban residents (-64%), women (-67%) and patients aged 18-49 (-66%) and 50-65 (-65%) years (Table 1). This study describes declines in troponin and LDL-C test volumes in the initial and second COVID-19 lockdown periods. Women had overall smaller total troponin and LDL-C test volumes and larger relative declines during the pandemic compared to men. The decrease in these ASCVD-related laboratory test volumes during the pandemic may have been accompanied by other important changes in indicators of healthcare utilization and associated clinical outcomes. Ongoing analyses will further explore the impact of the pandemic." @default.
• W3205253670 created "2021-10-25" @default.
• W3205253670 creator A5015536695 @default.
• W3205253670 creator A5030188902 @default.
• W3205253670 creator A5035792469 @default.
• W3205253670 creator A5037363341 @default.
• W3205253670 creator A5037522111 @default.
• W3205253670 creator A5037955905 @default.
• W3205253670 creator A5055992628 @default.
• W3205253670 creator A5062436710 @default.
• W3205253670 creator A5062563105 @default.
• W3205253670 creator A5080329053 @default.
• W3205253670 creator A5085675817 @default.
• W3205253670 date "2021-10-01" @default.
• W3205253670 modified "2023-10-18" @default.
• W3205253670 title "COVID-19 PANDEMIC INDUCED DISRUPTIONS IN TROPONIN AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL LABORATORY TEST VOLUMES ACROSS ALBERTA" @default.
• W3205253670 doi "https://doi.org/10.1016/j.cjca.2021.07.169" @default.
• W3205253670 hasPublicationYear "2021" @default.
• W3205253670 type Work @default.
• W3205253670 sameAs 3205253670 @default.
• W3205253670 citedByCount "0" @default.
• W3205253670 crossrefType "journal-article" @default.
• W3205253670 hasAuthorship W3205253670A5015536695 @default.
• W3205253670 hasAuthorship W3205253670A5030188902 @default.
• W3205253670 hasAuthorship W3205253670A5035792469 @default.
• W3205253670 hasAuthorship W3205253670A5037363341 @default.
• W3205253670 hasAuthorship W3205253670A5037522111 @default.
• W3205253670 hasAuthorship W3205253670A5037955905 @default.
• W3205253670 hasAuthorship W3205253670A5055992628 @default.
• W3205253670 hasAuthorship W3205253670A5062436710 @default.
• W3205253670 hasAuthorship W3205253670A5062563105 @default.
• W3205253670 hasAuthorship W3205253670A5080329053 @default.
• W3205253670 hasAuthorship W3205253670A5085675817 @default.
• W3205253670 hasBestOaLocation W32052536701 @default.
• W3205253670 hasConcept C115725540 @default.
• W3205253670 hasConcept C126322002 @default.
• W3205253670 hasConcept C142052008 @default.
• W3205253670 hasConcept C142724271 @default.
• W3205253670 hasConcept C144024400 @default.
• W3205253670 hasConcept C149923435 @default.
• W3205253670 hasConcept C2779134260 @default.
• W3205253670 hasConcept C2908647359 @default.
• W3205253670 hasConcept C3008058167 @default.
• W3205253670 hasConcept C500558357 @default.
• W3205253670 hasConcept C524204448 @default.
• W3205253670 hasConcept C71924100 @default.
• W3205253670 hasConcept C89623803 @default.
• W3205253670 hasConcept C99454951 @default.
• W3205253670 hasConceptScore W3205253670C115725540 @default.
• W3205253670 hasConceptScore W3205253670C126322002 @default.
• W3205253670 hasConceptScore W3205253670C142052008 @default.
• W3205253670 hasConceptScore W3205253670C142724271 @default.
• W3205253670 hasConceptScore W3205253670C144024400 @default.
• W3205253670 hasConceptScore W3205253670C149923435 @default.
• W3205253670 hasConceptScore W3205253670C2779134260 @default.
• W3205253670 hasConceptScore W3205253670C2908647359 @default.
• W3205253670 hasConceptScore W3205253670C3008058167 @default.
• W3205253670 hasConceptScore W3205253670C500558357 @default.
• W3205253670 hasConceptScore W3205253670C524204448 @default.
• W3205253670 hasConceptScore W3205253670C71924100 @default.
• W3205253670 hasConceptScore W3205253670C89623803 @default.
• W3205253670 hasConceptScore W3205253670C99454951 @default.
• W3205253670 hasIssue "10" @default.
• W3205253670 hasLocation W32052536701 @default.
• W3205253670 hasLocation W32052536702 @default.
• W3205253670 hasOpenAccess W3205253670 @default.
• W3205253670 hasPrimaryLocation W32052536701 @default.
• W3205253670 hasRelatedWork W3103289217 @default.
• W3205253670 hasRelatedWork W3106370311 @default.
• W3205253670 hasRelatedWork W3108360120 @default.
• W3205253670 hasRelatedWork W3119540162 @default.
• W3205253670 hasRelatedWork W3152916563 @default.
• W3205253670 hasRelatedWork W4226385797 @default.
• W3205253670 hasRelatedWork W4313474620 @default.
• W3205253670 hasRelatedWork W4327956415 @default.
• W3205253670 hasRelatedWork W4381432928 @default.
• W3205253670 hasRelatedWork W4381942459 @default.
• W3205253670 hasVolume "37" @default.
• W3205253670 isParatext "false" @default.
• W3205253670 isRetracted "false" @default.
• W3205253670 magId "3205253670" @default.
• W3205253670 workType "article" @default.